TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial
Brief Summary: It was aimed to examine the efficacy and safety of once daily dosage schema of colchicine in pediatric patients with FMF compared to twice daily dosage schema.

In this 24-week, multicentric, randomized, controlled, noninferiority trial, pediatric patients newly diagnosed with FMF, carrying homozygote or compound heterozygote mutation and did not receive any treatment, were included. Patients were randomly assigned using block randomization method to receive treatment with once or twice daily doses. Clinical and laboratory characteristics and medication side effects were recorded and compared between groups. The study complied with Good Clinical Practice and the Consolidated Standards for Reporting of Trials (CONSORT) statement.


Options:
A: Arm Label: once daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Arm Label: twice daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Intervention Type: DRUG; Name: colchicine; Assigned to Arm(s): once daily dosage schema of colchicine, twice daily dosage schema of colchicine
B: Arm Label: Canakinumab; Type: EXPERIMENTAL; Interventions: Drug: Canakinumab | Intervention Type: DRUG; Name: Canakinumab; Assigned to Arm(s): Canakinumab
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rilonacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo (for Rilonacept) and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Other: Placebo (for Rilonacept) | Arm Label: Rilonacept and Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Drug: Indomethacin | Arm Label: Rilonacept and Placebo (for Indomethacin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rilonacept, Other: Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): Rilonacept and Indomethacin, Rilonacept and Placebo (for Indomethacin) | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin, Rilonacept and Indomethacin | Intervention Type: OTHER; Name: Placebo (for Indomethacin); Assigned to Arm(s): Rilonacept and Placebo (for Indomethacin) | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo (for Rilonacept) and Indomethacin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial
Brief Summary: It was aimed to examine the efficacy and safety of once daily dosage schema of colchicine in pediatric patients with FMF compared to twice daily dosage schema.

In this 24-week, multicentric, randomized, controlled, noninferiority trial, pediatric patients newly diagnosed with FMF, carrying homozygote or compound heterozygote mutation and did not receive any treatment, were included. Patients were randomly assigned using block randomization method to receive treatment with once or twice daily doses. Clinical and laboratory characteristics and medication side effects were recorded and compared between groups. The study complied with Good Clinical Practice and the Consolidated Standards for Reporting of Trials (CONSORT) statement.


Options:
A: Arm Label: once daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Arm Label: twice daily dosage schema of colchicine; Type: EXPERIMENTAL; Interventions: Drug: colchicine | Intervention Type: DRUG; Name: colchicine; Assigned to Arm(s): once daily dosage schema of colchicine, twice daily dosage schema of colchicine
B: Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Kineret | Arm Label: Kineret (Anakinra); Type: EXPERIMENTAL; Interventions: Drug: Kineret | Intervention Type: DRUG; Name: Kineret; Assigned to Arm(s): Kineret (Anakinra), Vehicle
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: rilonacept 160 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: rilonacept 160 mg | Arm Label: Open-Label rilonacept 160 mg; Type: OTHER; Interventions: Drug: rilonacept 160 mg | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): rilonacept 160 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: rilonacept 160 mg; Assigned to Arm(s): Open-Label rilonacept 160 mg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rilonacept | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rilonacept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prone Position Effects on Work of Breathing and Intrinsic PEEP in Children With Severe Acute Viral Bronchiolitis
Brief Summary: Acute viral bronchiolitis is the first cause of respiratory distress in infant. Airway inflammation increases the respiratory system resistances and dynamic hyperinflation. This leads to an increase in the work of breathing. In Chronic obstructive pulmonary disease patients as in neonates, prone position (PP) improves lung function and decreases the end expiratory lung volume. The investigators hypothesized that in infants with severe bronchiolitis, prone position reduces the intrinsic Positive End Expiratory Pressure (PEEPi) and the work of breathing (WOB). The investigator designed a prospective randomized crossover study with 16 infants younger than six months who need ventilatory support by nasal continuous positive airway pressure (nCPAP) for severe acute viral bronchiolitis. Work of breathing (product time pressure) and PEEPi will be estimated using an esophageal pressure probe in prone and supine position.


Options:
A: Arm Label: Semirecumbent position; Type: ACTIVE_COMPARATOR; Interventions: Other: lateral-Trendelenburg position | Arm Label: lateral-Trendelenburg position; Type: EXPERIMENTAL; Interventions: Other: lateral-Trendelenburg position | Intervention Type: OTHER; Name: lateral-Trendelenburg position; Assigned to Arm(s): Semirecumbent position, lateral-Trendelenburg position
B: Arm Label: Repetitive recruitment with PEEP; Type: EXPERIMENTAL; Interventions: Procedure: Repetitive recruitment with PEEP | Arm Label: One recruitment with PEEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: One recruitment with PEEP | Intervention Type: PROCEDURE; Name: Repetitive recruitment with PEEP; Assigned to Arm(s): Repetitive recruitment with PEEP | Intervention Type: PROCEDURE; Name: One recruitment with PEEP; Assigned to Arm(s): One recruitment with PEEP
C: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Procedure: Trendelenburg position | Intervention Type: PROCEDURE; Name: Trendelenburg position; Assigned to Arm(s): Single arm
D: Arm Label: PRONE-Supine; Type: EXPERIMENTAL; Interventions: Procedure: Prone then supine position | Arm Label: SUPINE - Prone; Type: EXPERIMENTAL; Interventions: Procedure: Supine then Prone position | Intervention Type: PROCEDURE; Name: Supine then Prone position; Assigned to Arm(s): SUPINE - Prone | Intervention Type: PROCEDURE; Name: Prone then supine position; Assigned to Arm(s): PRONE-Supine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed
Brief Summary: The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.


Options:
A: Arm Label: Continuous quality improvement (CQI); Type: EXPERIMENTAL; Interventions: Other: Continuous quality improvement | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Continuous quality improvement; Assigned to Arm(s): Continuous quality improvement (CQI)
B: Arm Label: Control arm: HBIG & vaccine for infants; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TDF treatment arm; Type: EXPERIMENTAL; Interventions: Drug: TDF treatment | Intervention Type: DRUG; Name: TDF treatment; Assigned to Arm(s): TDF treatment arm
C: Arm Label: Blinded Phase: B/F/TAF; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF, Drug: ABC/DTG/3TC Placebo | Arm Label: Blinded Phase: ABC/DTG/3TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABC/DTG/3TC, Drug: B/F/TAF Placebo | Arm Label: Open-Label Phase; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF | Intervention Type: DRUG; Name: ABC/DTG/3TC; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC | Intervention Type: DRUG; Name: B/F/TAF; Assigned to Arm(s): Blinded Phase: B/F/TAF, Open-Label Phase | Intervention Type: DRUG; Name: ABC/DTG/3TC Placebo; Assigned to Arm(s): Blinded Phase: B/F/TAF | Intervention Type: DRUG; Name: B/F/TAF Placebo; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC
D: Arm Label: 2A; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 2A | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2, Dose-finding Study With ACT-132577 in Subjects With Essential Hypertension (Grade 1 and 2).
Brief Summary: The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.

Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
B: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aprocitentan 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 5 mg | Arm Label: Aprocitentan 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 10 mg | Arm Label: Aprocitentan 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 25 mg | Arm Label: Aprocitentan 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 50 mg | Arm Label: Lisinopril 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril 20 mg | Intervention Type: DRUG; Name: Aprocitentan 5 mg; Assigned to Arm(s): Aprocitentan 5 mg | Intervention Type: DRUG; Name: Aprocitentan 10 mg; Assigned to Arm(s): Aprocitentan 10 mg | Intervention Type: DRUG; Name: Aprocitentan 25 mg; Assigned to Arm(s): Aprocitentan 25 mg | Intervention Type: DRUG; Name: Aprocitentan 50 mg; Assigned to Arm(s): Aprocitentan 50 mg | Intervention Type: DRUG; Name: Lisinopril 20 mg; Assigned to Arm(s): Lisinopril 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ambrisentan; Type: ACTIVE_COMPARATOR; Interventions: Drug: ambrisentan | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): ambrisentan, sugar pill

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ontario Appropriate Prescribing Demonstration Project: Pragmatic, Cluster-Randomized Clinical Trial to Reduce Antipsychotic Medication Prescribing in Long-Term Care Homes
Brief Summary: Two arm, pragmatic, cluster-randomized trial, with nursing homes allocated to the full, active intervention (featuring educational outreach offered to each prescriber and team members in the home) or standard quality improvement supports (including online audit and feedback reports for each prescriber in the home). The 'standard' quality improvement supports represent 'usual care' as these are to be launched province-wide; a concurrent control arm with no exposure to a quality improvement intervention is not feasible.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TREA (Treatment Routes for Exploring Agitation) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo Control Group | Intervention Type: BEHAVIORAL; Name: TREA (Treatment Routes for Exploring Agitation); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Placebo Control Group; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care
D: Arm Label: Audit + Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit + Feedback | Arm Label: Audit + Feedback + Educational Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback; Assigned to Arm(s): Audit + Feedback, Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback + Educational Outreach; Assigned to Arm(s): Audit + Feedback + Educational Outreach

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ontario Appropriate Prescribing Demonstration Project: Pragmatic, Cluster-Randomized Clinical Trial to Reduce Antipsychotic Medication Prescribing in Long-Term Care Homes
Brief Summary: Two arm, pragmatic, cluster-randomized trial, with nursing homes allocated to the full, active intervention (featuring educational outreach offered to each prescriber and team members in the home) or standard quality improvement supports (including online audit and feedback reports for each prescriber in the home). The 'standard' quality improvement supports represent 'usual care' as these are to be launched province-wide; a concurrent control arm with no exposure to a quality improvement intervention is not feasible.


Options:
A: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: EHR Based Strategy to promote Safe and Appropriate Drug Use | Arm Label: Standard Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EHR Based Strategy to promote Safe and Appropriate Drug Use; Assigned to Arm(s): Intervention Arm
B: Arm Label: ISTOP-ADE; Type: EXPERIMENTAL; Interventions: Other: ISTOP-ADE | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ISTOP-ADE; Assigned to Arm(s): ISTOP-ADE
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Virtual Ward; Type: EXPERIMENTAL; Interventions: Other: Virtual Ward | Intervention Type: OTHER; Name: Virtual Ward; Assigned to Arm(s): Virtual Ward | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
D: Arm Label: Audit + Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit + Feedback | Arm Label: Audit + Feedback + Educational Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback; Assigned to Arm(s): Audit + Feedback, Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback + Educational Outreach; Assigned to Arm(s): Audit + Feedback + Educational Outreach

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
Brief Summary: To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.


Options:
A: Arm Label: ClearGuard HD end cap; Type: ACTIVE_COMPARATOR; Interventions: Device: ClearGuard HD end cap | Arm Label: Standard hemodialysis end cap; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ClearGuard HD end cap; Assigned to Arm(s): ClearGuard HD end cap
B: Intervention Type: DRUG; Name: Ethanol; Assigned to Arm(s): N/A
C: Arm Label: NAC/Tigecycline/Heparin combination lock solution; Type: EXPERIMENTAL; Interventions: Drug: NAC/Tigecycline/Heparin combination lock solution | Arm Label: Standard anticoagulant (heparin or citrate); Type: PLACEBO_COMPARATOR; Interventions: Drug: Standard anticoagulant (Heparin or Citrate) | Intervention Type: DRUG; Name: NAC/Tigecycline/Heparin combination lock solution; Assigned to Arm(s): NAC/Tigecycline/Heparin combination lock solution | Intervention Type: DRUG; Name: Standard anticoagulant (Heparin or Citrate); Assigned to Arm(s): Standard anticoagulant (heparin or citrate)
D: Arm Label: group A; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Arm Label: group B; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Intervention Type: DEVICE; Name: catheter replacement; Assigned to Arm(s): group A, group B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Brief Summary: The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg
B: Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
D: Arm Label: SHP465 12.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SHP465 12.5mg capsules (one capsule daily) | Arm Label: SHP465 37.5 mg; Type: EXPERIMENTAL; Interventions: Drug: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SHP465 12.5mg capsules (one capsule daily); Assigned to Arm(s): SHP465 12.5 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily); Assigned to Arm(s): SHP465 37.5 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Brief Summary: A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.


Options:
A: Arm Label: Flovent 1760 mcg; Type: EXPERIMENTAL; Interventions: Drug: Flovent | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Flovent; Assigned to Arm(s): Flovent 1760 mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Oral Budesonide Suspension (OBS); Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (OBS); Assigned to Arm(s): Oral Budesonide Suspension (OBS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Oral cromolyn; Type: EXPERIMENTAL; Interventions: Drug: oral cromolyn sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: oral cromolyn sodium; Assigned to Arm(s): Oral cromolyn | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): 1

Answer: B